Company intelligence / Profile preview
Guangzhou Zaiji Medical Technology
Guangzhou, Guangdong Sheng, Chinamaxinovel.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangzhou Zaiji Medical Technology has a pipeline focused on small molecules and radiopharmaceuticals for oncology, immune, hematologic, and nervous system indications. At least one program combines MAX‑40279‑01 with toripalimab for solid tumors in early clinical trials. The company has conducted approximately ten clinical trials as of mid‑2025.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Small moleculeRadiopharmaceuticals and diagnostic agent
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Toripalimab collaboration
Beyond the preview
Go deeper on Guangzhou Zaiji Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Zaiji Medical Technology.